Research Topics
Genomes and Genes | Adrian M Di BisceglieSummaryAffiliation: Saint Louis University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A 32-year-old man with hepatitis C who developed progressive liver failure after a bone marrow transplantAndre C Lyra
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Ave, St. Louis, MO 63110, USA
Semin Liver Dis 22:103-8. 2002- Epidemiology and clinical presentation of hepatocellular carcinomaAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3634 Vista Avenue, St Louis, MO 63110, USA
J Vasc Interv Radiol 13:S169-71. 2002..Early detection of HCC is a key factor in improving outcomes of therapies. There is growing evidence that HCC may be prevented with strategies aimed at preventing or treating viral hepatitis... - Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis CAlan Lee Rothman
Center for Infectious Disease and Vaccine Research and Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
Hepatology 41:617-25. 2005.... - Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis CA M Di Bisceglie
Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO 63110, USA
J Viral Hepat 14:721-9. 2007.... 
Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5aZekuan Xu
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
J Virol 82:9417-24. 2008..Furthermore, the pattern for mutation clustering indicated potential mutation linkage among E2, NS2, and NS5a due to structural or functional relatedness in HCV replication...- The history of the Department of Internal Medicine at Saint Louis UniversityAdrian M Di Bisceglie
Department of Internal Medicine, Saint Louis University Liver Center, USA
Mo Med 109:115-8. 2012..The department has played a key role in several medical discoveries and innovations over the last 100 years and continues to make an impact on those in its community... 
Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysisStephen J Polyak
Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
Virol J 2:41. 2005..QS diversity and complexity were quantified using heteroduplex mobility assays (HMA)...- Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trialA M Di Bisceglie
Saint Louis University School of Medicine, St Louis, MO 63104, USA
Hepatology 32:135-8. 2000.... - Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responderAdrian M Di Bisceglie
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Saint Louis University Liver Center, Saint Louis University School of Medicine, St Louis, Missouri 63110, USA
J Med Virol 78:446-51. 2006.... - HIV-HBV coinfection among South African patients receiving antiretroviral therapyAdrian M Di Bisceglie
Department of Internal Medicine, Saint Louis University, St Louis, MO, USA
Antivir Ther 15:499-503. 2010..Additional information is needed on the prevalence of HIV-HBV coinfection and treatment response to ART. We present a summary of the information available from South Africa to date... - Pretransplant treatments for hepatocellular carcinoma: do they improve outcomes?Adrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Saint Louis University Liver Center, Saint Louis University School of Medicine, St Louis, MO 63110, USA
Liver Transpl . 2005..3. Prospective, randomized controlled trials are clearly needed to determine if pre-transplant therapy of HCC is of value... - Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C TrialAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
J Hepatol 43:434-41. 2005..We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy... - Chemoprevention of hepatocellular carcinoma: use of tamoxifen in an animal model of hepatocarcinogenesisAdrian M Di Bisceglie
Saint Louis University Liver Center, Department of Medicine, Saint Louis University, 3635 Vista Ave at Grand Blvd, MO 63110, USA
J Lab Clin Med 145:134-8. 2005.... - Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferonAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO, USA
Hepatology 53:1100-8. 2011..CONCLUSION: Long-term maintenance peginterferon in patients with advanced chronic hepatitis C is associated with an excess overall mortality, which was primarily due to nonliver-related causes among patients with bridging fibrosis... - Long term follow up of bone mineral density in patients with primary biliary cirrhosisA M Di Bisceglie
Division of Gastroenterology and Hepatology, Saint Louis University, Saint Louis, MO 63110, USA
Minerva Med 95:529-34. 2004.... - Spontaneous retroperitoneal and rectus muscle hemorrhage as a potentially lethal complication of cirrhosisAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Saint Louis University Liver Center, Saint Louis University School of Medicine, St Louis, MO 63110, USA
Liver Int 26:1291-3. 2006..Cirrhosis may be complicated by bleeding from varices at sites of porto-systemic anastomosis and may be exacerbated by coagulopathy... - Issues in screening and surveillance for hepatocellular carcinomaAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, Missouri 63110, USA
Gastroenterology 127:S104-7. 2004..Clearly, better methods are needed for early diagnosis of HCC. Improved technology will ultimately have to be tested for improved patient outcome before becoming widely recommended... - Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferonAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Ave, St Louis, MO 63110, USA
N Engl J Med 359:2429-41. 2008..Whether long-term antiviral therapy can prevent progressive liver disease in such patients remains uncertain... - Optimal therapy of hepatitis CAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology and the Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis University, St Louis, MO 63110, USA
Hepatology 36:S121-7. 2002.... - The AASLD and public policy: coming in out of the coldAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, University Liver Center, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO 63110, USA
Hepatology 45:1335-6. 2007 - Combination therapy for hepatitis BA M Di Bisceglie
Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO 63110, USA
Gut 50:443-5. 2002..New drugs acting by different antiviral mechanisms may be particularly potent in combination... - Hepatitis B and hepatocellular carcinomaAdrian M Di Bisceglie
Saint Louis University Liver Center, Saint Louis University, St Louis, MO 63110, USA
Hepatology 49:S56-60. 2009..There are emerging data showing that prolonged antiviral therapy may reduce the risk of hepatocellular carcinoma among certain patients with chronic hepatitis B... - Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patientsMaureen J Donlin
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, Missouri, United States of America
PLoS ONE 5:e9032. 2010..African American patients respond to interferon alpha-based therapy at about half the rate of Caucasian Americans. The effect of HCV's genetic variation on treatment outcome in both racial groups is poorly understood... - Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson
Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
Hepatology 44:1675-84. 2006..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients... - Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patientsSarah L George
Department of Internal Medicine, Division of Gastroenterology, Saint Louis University Liver Center, St Louis, MO, USA
Hepatology 49:729-38. 2009..A minority of patients had normal or nearly normal liver tissue on long-term follow-up biopsy. Patients with cirrhosis pretreatment are at a low but real risk of HCC after SVR... - Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis CRichard W Lambrecht
Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA
Gastroenterology 140:1490-500.e3. 2011..Our aim was to assess the relationship of iron and HFE genetic variations to progression and outcomes in the HALT-C Trial and whether PegIFN therapy influenced iron variables... - Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis CStephen A Harrison
Saint Louis University Liver Center, Saint Louis University, St Louis, MS, USA
Clin Gastroenterol Hepatol 3:604-9. 2005..A control group (group 2) of 231 CHC patients was identified by using a 2-year database (January 2000-June 2001) of patients without evidence of greater than 33% steatosis or SH... - Liver transplantation with hepatitis C virus-infected graft: interaction between donor and recipient viral strainsXiaofeng Fan
Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MO, USA
Hepatology 38:25-33. 2003..In conclusion, in all 6 cases studied, there was no genetic recombination detected among HCV quasispecies or between donor and recipient HCV strains... - Infection with hepatitis C virus genotype 4 in the United StatesAndre C Lyra
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO 63110, USA
J Clin Gastroenterol 38:68-71. 2004.... - A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinomaBarham K Abu Dayyeh
Gastrointestinal Unit, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114, USA
Gastroenterology 141:141-9. 2011..We tested associations between demographic, clinical, and genetic data and development of HCC, and developed a simple predictive model in a cohort of patients with chronic hepatitis C and advanced fibrosis... 
Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in EgyptSoo Hyung Ryu
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University Liver Center, Saint Louis University School of Medicine, St Louis, MO 63110, USA
J Med Virol 81:844-7. 2009..08). In conclusion, HCV genotype 4 predominates in Egypt. There was no association between subtypes of genotype 4 and the development of HCC...- Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapyMaureen J Donlin
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, 1402 S Grand Blvd, Saint Louis, MO 63104, USA
J Virol 81:8211-24. 2007..No evidence was found for novel HCV strains in the AA population, implying that AA patients may be infected with a higher proportion of the same resistant strains that are found in CA patients... - Evolution of hepatitis C viral quasispecies after liver transplantationAndre C Lyra
Division of Gastroenterology and Hepatology, Department of Internal Medicine and Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, Missouri 63110, USA
Gastroenterology 123:1485-93. 2002..Among those patients with severe recurrent hepatitis C, HCV appeared to be under greater immune pressure. The greatest change in viral amino acid sequences occurred in the first 36 months after OLT... - Hepatitis C virus-mediated inhibition of cathepsin S increases invariant-chain expression on hepatocyte surfaceHangeun Kim
Department of Internal Medicine, Saint Louis University, Saint Louis, Missouri, USA
J Virol 86:9919-28. 2012.... - Hepatitis C virus proteins inhibit C3 complement productionBudhaditya Mazumdar
Departments of Internal Medicine, Saint Louis University, Saint Louis, Missouri, USA
J Virol 86:2221-8. 2012..Together, these results underscore the role of HCV NS5A protein in impairing innate immune function... - The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinomaXiaoan Zhang
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, MO 63104, USA
J Clin Virol 52:333-8. 2011..As HCV shows remarkable genetic diversity, an interesting and important issue is whether such a high viral genetic diversity plays a role in the incidence of HCC. Prior data on this subject are conflicting... - Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinomaElizabeth M Brunt
Department of Pathology, Saint Louis University School of Medicine, St Louis, MO 63110, USA
Liver Int 27:662-71. 2007..Histologic markers to predict hepatocellular carcinoma (HCC) include small cell change and dysplastic nodules. Hepatocyte senescence is noted in chronic liver disease and may or may not be important in progression to HCC... - Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis CRobert J Fontana
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0362, USA
Gastroenterology 138:2321-31, 2331.e1-2. 2010..We aimed to identify the incidence and predictors of de novo gastroesophageal variceal formation and progression in a large cohort of patients with chronic hepatitis C and advanced fibrosis... - Separation of near full-length hepatitis C virus quasispecies variants from a complex populationDonghui Zhou
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, MO 63104, USA
J Virol Methods 141:220-4. 2007..These observations emphasize the significance of the use of near full-length genomic sequences for HCV genetic studies and for reverse genetic analysis using authentic quasispecies variants... - Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis CAnna S Lok
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Hepatology 54:434-42. 2011..In the United States, neither previous nor occult HBV infection is an important factor in HCC development among patients with advanced chronic hepatitis C... - CD81 binding regions of hepatitis C virus remain conserved after liver transplantationAndre C Lyra
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA
Braz J Infect Dis 8:126-32. 2004..This may favor HCV re-infection of the allograft after liver transplantation... - Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic statusAdrian M Di Bisceglie
Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri 63110, USA
Am J Gastroenterol 98:2060-3. 2003..These preliminary findings indicate the need for a more detailed study of ethnic variability in the pathogenesis of HCC... - High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapyXiaofeng Fan
Division of Gastroenterology and Hepatology, Department of Internal Medicine, St Louis University School of Medicine, St Louis, MO, USA
Hepatology 50:1765-72. 2009..CONCLUSION: EVR is associated with elevated HCV QS diversity and complexity, especially in patients with significantly higher HCV genetic heterogeneity... - The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcomeAlex S Befeler
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University, St Louis, MO 63110, USA
Arch Surg 140:650-4; discussion 655. 2005..Patients with cirrhosis with hemoglobin levels lower than 10 g/dL should receive corrective blood transfusions before abdominal surgery... - Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantationWeihua Wang
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, MO 63104, USA
Biochem Biophys Res Commun 414:148-52. 2011..Instead, our data suggested an essential role of the fitness adaptation of founder viral population in driving such an evolutionary pattern... - A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: does nursing play a role?Janice M Strinko
Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA
Issues Ment Health Nurs 25:715-22. 2004..Eighty-one percent of sustained responders experienced psychiatric events, and it is speculated that comprehensive nursing support and intervention were key components in achieving favorable patient outcomes... - The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinomaPaul H Hayashi
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University Liver Center, 3635 Vista Avenue, St Louis, Mo 63110 0250, USA
Med Clin North Am 89:345-69. 2005..It is hoped that antiviral treatment studies will lower the risk of HCC, and that these changes will occur soon enough to help the many patients at risk for or diagnosed with HCC over the next several years... - The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesisPaul H Hayashi
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University Liver Center, 3635 Vista Avenue, St Louis, Mo 63110 0250, USA
Med Clin North Am 89:371-89. 2005..Understanding of this epidemiology and pathophysiology provides the basis for the clinical evaluation, diagnosis, screening, and treatment of HCC... - Diversification of hypervariable region 1 of hepatitis C virus after liver transplantationXiaofeng Fan
Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri 63110-0250, USA
J Med Virol 70:212-8. 2003..However, the dramatic diversification of HVR1 sequence over time is mainly due to the adaptation of new replicative site, the donor liver, indicating that HCV may obtain the higher replication fitness by mutating HVR1 domain... - Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130AJoydip Bhanja Chowdhury
Department of Pathology, Saint Louis University, Saint Louis, Missouri, USA
J Virol 86:10221-5. 2012..Hepatocytes stably expressing IFITM1 reduced HCV replication. Together, these results suggested that HCV infection of hepatocytes upregulates miR-130a and that use of anti-miR-130a may have potential for restriction of HCV replication... - Transcriptional repression of C4 complement by hepatitis C virus proteinsArup Banerjee
Department of Internal Medicine, Saint Louis University, 1100 S Grand Blvd, 8th Floor, St Louis, MO 63104, USA
J Virol 85:4157-66. 2011..These results underscore the roles of HCV proteins in innate immune regulation in establishing a chronic infection... - Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis CHerbert L Bonkovsky
Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA
Gastroenterology 131:1440-51. 2006.... - Diabetic hepatosclerosis: diabetic microangiopathy of the liverStephen A Harrison
Liver Center, Department of Medicine, Saint Louis University School of Medicine, St Louis, MO 63110, USA
Arch Pathol Lab Med 130:27-32. 2006..Further studies are needed to precisely characterize diabetic hepatosclerosis and to understand mechanisms of pathogenesis and the clinical significance... - New therapeutic strategies for hepatitis CAdrian M Di Bisceglie
Saint Louis University, St. Louis MO 63110, USA
Hepatology 35:224-31. 2002 - Enhanced protocol for determining the 3' terminus of hepatitis C virusXiaoan Zhang
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, MO 63110, USA
J Virol Methods 167:158-64. 2010..The availability of abundant authentic sequence information for the complete HCV 3'UTR will allow full investigation of its biological role in the life cycle of HCV... - Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samplesXiaofeng Fan
Division of Gastroenterology and Hepatology, Saint Louis University Liver Center, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, MO 63110, USA
Biochem Biophys Res Commun 346:1163-72. 2006..Thus, our LRP protocol could be applied for the amplification of other difficult RNA templates and may facilitate RNA virus research such as linked viral mutations and reverse genetics... - RT-PCR amplification and cloning of large viral sequencesXiaofeng Fan
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University Liver Center, Saint Louis University School of Medicine, St Louis, MO, USA
Methods Mol Biol 630:139-49. 2010.... - Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinomaEldad S Bialecki
Department of Internal Medicine, Saint Louis University School of Medicine St Louis, Missouri, USA
Clin Gastroenterol Hepatol 4:361-8. 2006..Obtaining material for both cytologic and histologic examination at biopsy maximizes the diagnostic yield... - Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytesArnab Basu
Department of Internal Medicine, Liver Center and Cancer Center, Saint Louis University, St. Louis, MO 63110, USA
Virology 349:347-58. 2006..Identification of these modulated genes with potential roles may help in the selection of targets for therapies against HCV-mediated liver disease progression... - Liver transplantation for hepatocellular carcinomaAlex S Befeler
Saint Louis University Liver Center, Saint Louis University, Missouri 63110, USA
Gastroenterology 128:1752-64. 2005 - Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostainingJohn Richart
Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri 63104, USA
Dig Dis Sci 47:2454-8. 2002.... - Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogeneticsJohn E Tavis
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA
Genome Med 3:8. 2011..Direct-acting inhibitors of HCV that will be used in combination with IFNα are nearing approval, so genetic prediction for anti-HCV therapy will soon need to incorporate viral genetic markers of viral resistance to the new drugs... - Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case reportElizabeth M Brunt
Saint Louis University Liver Center, Saint Louis University Health Sciences Center, St. Louis, Missouri 63110, USA
Semin Liver Dis 25:230-6. 2005 - Genetic complexity and serum reactivity of HVR1 quasispecies of hepatitis C virus in patients with cirrhosisXiaofeng Fan
Department of Internal Medicine, Saint Louis University School of Medicine, Missouri 63110 0250, USA
Am J Gastroenterol 97:1489-95. 2002..However, the significance of this finding has not been examined extensively at genetic and serological levels... - Hepatocellular carcinoma: diagnosis and treatmentAlex S Befeler
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO 63110, USA
Gastroenterology 122:1609-19. 2002..Identifying hepatocellular carcinoma at an early stage is often associated with having better treatment options for patients with small, asymptomatic tumors... - HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processingTiffany Slater-Handshy
Department of Molecular Microbiology and Immunology, St Louis University School of Medicine, St Louis, MO 63104, USA
Virology 319:36-48. 2004..These experiments provide direct evidence that the presence of multiple N-linked glycans is required for the proper folding of the E2 protein in the ER and secretory pathway as well as for formation of its antigenic structure... - Aging liver and hepatitisOmer Junaidi
Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, Saint Louis, MO 63110, USA
Clin Geriatr Med 23:889-903, viii. 2007..This article reviews the likely causes of hepatitis in elderly individuals and discusses evidence for treating this population... - Advances in the understanding and treatment of nonalcoholic fatty liver diseaseStephen A Harrison
Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, Missouri, USA
Drugs 63:2379-94. 2003.... - Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitisMark D Murray
Division of Gastroenterology and Hepatology, Saint Louis University Liver Center, Saint Louis University School of Medicine, St Louis, MO 63110, USA
J Clin Gastroenterol 41:115-7. 2007..We conclude that serum CA 19-9 levels need to be assessed in the clinical context of biliary obstruction and should ideally be measured after relief of that obstruction, as it may be falsely elevated due to benign biliary strictures... - Clinical presentation and natural course of hepatocellular carcinomaEldad S Bialecki
Division of Gastroenterology and Hepatology, Saint Louis University Liver Center, USA
Eur J Gastroenterol Hepatol 17:485-9. 2005..Growth and maturation of hepatocellular carcinoma is variable and involves a complex network of hepatic vasculature. Staging systems have been developed to predict disease progression and survival and continue to undergo investigation... - Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adultsSharon E Frey
Saint Louis University School of Medicine, Division of Infectious Diseases and Immunology, St Louis, MO 63104, USA
Vaccine 28:6367-73. 2010..We describe the first in humans clinical trial of this prophylactic HCV vaccine... - Biliary-venous fistula complicating transjugular intrahepatic portosystemic shunt presenting with recurrent bacteremia, jaundice, anemia and feverQaiser Jawaid
Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, Saint Louis, MO, USA
Am J Transplant 3:1604-7. 2003..Liver transplantation may be the preferred treatment if TIPS becomes infected following its complete occlusion... - Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoproteinKeith Meyer
Department of Internal Medicine, Saint Louis University, 3635 Vista Ave, St. Louis, Missouri 63110, USA
J Virol 76:2150-8. 2002.... - Procarbazine-induced hepatotoxicity: case report and review of the literatureMark J Fesler
Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri 63110, USA
Pharmacotherapy 30:540. 2010..Based on our experience with this patient, periodic assessment of hepatic function, as suggested in the package insert, is recommended in patients receiving procarbazine... - Direct evidence for GB virus C/hepatitis G virus (GBV-C/HGV) superinfection: elimination of resident viral strain by donor strain in a patient undergoing liver transplantationXiaofeng Fan
Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri 63104, USA
J Med Virol 68:76-81. 2002..This study, therefore, provides direct evidence for GBV-C/HGV superinfection of one strain by another with one of them predominating probably due to replication competition... - A new approach to therapy for hepatocellular carcinoma?Stephen A Harrison
Saint Louis University, MO, USA
Hepatology 37:471-3. 2003 - Concurrence of histologic features of steatohepatitis with other forms of chronic liver diseaseElizabeth M Brunt
Saint Louis University Liver Center Department of Pathology, Saint Louis University Health Sciences Center, St Louis, Missouri, USA
Mod Pathol 16:49-56. 2003..Diabetes was reported in 35%, 25%, and 9%. The concurrence of clinical and histologic features of steatohepatitis with another chronic liver disease may be a reflection of the frequency of steatohepatitis in the population at large... - Histological changes after the use of mycophenolate mofetil in autoimmune hepatitisElizabeth M Brunt
Saint Louis University Liver Center, Saint Louis University Health Sciences Center, St. Louis, MO, USA
Hum Pathol 35:509-12. 2004..Both cytoplasmic features of adaptation and nuclear alterations were noted in hepatocytes. Possible mechanisms for these findings are discussed... - Testing for hepatitis C virus infection should be routine for persons at increased risk for infectionMiriam J Alter
Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
Ann Intern Med 141:715-7. 2004.... - Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespondersWilliam M Lee
Control Clin Trials 25:472-92. 2004..The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity... - Screening for hepatocellular carcinoma: being old is not all badAdrian M Di Bisceglie
Am J Gastroenterol 99:1477-8. 2004..Thus, specialized liver centers have to deal with larger number of patients with HCC... - Design and endpoints of clinical trials in hepatocellular carcinomaJosep M Llovet
HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
J Natl Cancer Inst 100:698-711. 2008..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC... - Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatmentMitchell L Shiffman
Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
Gastroenterology 126:1015-23; discussion 947. 2004..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy... - What every hepatologist should know about endocrinology: obesity, diabetes, and liver diseaseAdrian M Di Bisceglie
Gastroenterology 126:604-6. 2004 - Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohortAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
Hepatology 42:282-92. 2005..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC... - Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis CDavid Butera
Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, Box 64, 1230 York Ave, New York, NY 10021, USA
Blood 106:1175-82. 2005..This observation has implications for understanding the pathogenesis of HCV infection... - Serum activity of alanine aminotransferase (ALT) as an indicator of health and diseaseW Ray Kim
Mayo Clinic College of Medicine, Rochester, MN, USA
Hepatology 47:1363-70. 2008 - Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) TrialLeonard B Seeff
Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Hepatology 47:605-12. 2008..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C... - Telbivudine versus lamivudine in patients with chronic hepatitis BChing Lung Lai
University Department of Medicine, Queen Mary Hospital, Hong Kong, China
N Engl J Med 357:2576-88. 2007..Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B... - Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trialAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
Clin Gastroenterol Hepatol 5:245-54. 2007.... - Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis CMitchell L Shiffman
Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
Gastroenterology 132:103-12. 2007..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment... - Health-related quality of life in patients with chronic hepatitis C and advanced fibrosisHerbert L Bonkovsky
Liver Biliary Pancreatic Center and the Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA
J Hepatol 46:420-31. 2007..This study assessed HRQOL and sexual health in patients with advanced fibrosis or cirrhosis in the HALT-C Trial... - The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosisArun J Sanyal
Division of Gastroenterology, Virginia Commonwealth University Health System, Richmond, Virginia, USA
Gastrointest Endosc 64:855-64. 2006..758). CONCLUSIONS: The risk of having varices increases with decreasing platelet counts, increasing bilirubin, and INR. The probability of having medium or large varices at platelet counts >150,000/mm(3) is negligible in this population... - HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trialChihiro Morishima
Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
Hepatology 44:360-7. 2006..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did... - Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis CChihiro Morishima
Department of Laboratory Medicine and Pediatrics, University of Washington, Seattle, USA
J Infect Dis 193:931-40. 2006..Thus, in patients with advanced hepatic fibrosis due to HCV infection, pretreatment HCV-specific immune responses and increased QS variability appear to hinder viral clearance by pegylated IFN- alpha 2a and ribavirin combination therapy... - Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried
University of North Carolina, Chapel Hill, NC 27514, USA
Hepatology 48:1033-43. 2008....
Research Grants
- HEPATITIS C VIRAL QUASISPECIES WITHIN THE LIVERAdrian Di Bisceglie; Fiscal Year: 2003..These studies have great potential significance for understanding of viral clearance, development of persistent infection and for the development of a vaccine against HCV. ..